Larimar Therapeutics is under investigation by Pomerantz LLP for potential securities fraud related to safety issues in its drug trials for nomlabofusp, a treatment for Friedreich's Ataxia. Despite positive data claims, reports of severe allergic reactions (anaphylaxis) in multiple patients led to significant stock price declines in September 2025 and June 2026. The investigation could impact investor confidence and the company's regulatory progress. Investors are advised to contact Pomerantz LLP for more information or to join the class action.
Idaho Copper Corporation announced an $18 million public offering of common stock and warrants priced at $4.85 per share, with an additional 45-day option for over-allotments. The proceeds will fund an updated Preliminary Economic Assessment, initial...
The global neonatal infant care market, valued at $3.06 billion in 2025, is projected to grow to $5.59 billion by 2035 at a CAGR of 6.21%. Growth is driven by increasing preterm births and neonatal complications like respiratory disorders and jaundic...
The FDA has approved Casgevy, a gene therapy using CRISPR technology, for children aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This therapy modifies patients' own stem cells to increase fetal hemo...
ClearBridge Energy Midstream Opportunity Fund (EMO) maintains a hold rating due to its attractive 8.6% monthly dividend yield, supported by earnings and tax-efficient distributions. However, the fund's concentrated exposure to a few midstream energy ...
Telix Pharmaceuticals received FDA agreement to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration resistant prostate cancer in the U.S. The FDA approved the clinical protocol, statistical plan, and safety data...
